During titration , incidences of treatment-emergent adverse events ( TEAEs ) were 50.0 % ( 169/338 ) with tapentadol PR and 63.9 % ( 101/158 ) with morphine CR ; incidences of nausea , vomiting , and dry mouth were lower with tapentadol PR than with morphine CR .